The DOI matches its Crossref record.
Cell Cycle Molecular Targets in Novel Anticancer Drug Discovery
Abstract
A number of potential molecular targets for novel anticancer drug discovery have been identified in cell cycle control mechanisms. Prominent among these are the regulatory proteins, cyclins and their effector counterparts the cyclin dependent kinases (CDKs). Aberrant expression of these proteins, particularly cyclins involved in the G1 phase of the cell cycle, namely the D and E cyclins, has been associated with a variety of human cancers, including breast and colorectal cancer, B-lymphoma, prostate and non-small cell lung cancer. Inhibition of CDK kinase activity has turned out to be the most productive strategy for the discovery and design novel anticancer agents specifically targeting the cell cycle. Other potentially useful cell cycle areas for exploration include cyclin-CDK interactions, Cdc25 activation of cyclin-CDK complexes, ubiquitin-mediated proteolysis of cyclins, cell cycle check point kinases like Chk1, and recently identified oncogenic cell cycle-related aurora and polo-like kinases. Potent specific inhibitors have been identified that bind to the ATP site of CDKs, mainly cyclin B-CDK1, cyclin A-CDK2, and cyclin D-CDK4 complexes, and inhibit kinase activity. X-ray crystallographic data of CDKs, and their complexes with inhibitors have played a major role in the success of drug discovery efforts. Combinatorial chemistry, highthroughput screening, functional genomics and informatics have also contributed. CDK inhibitors currently under investigation include flavopiridol, olomoucine, roscovitine, puvalanol B, the dihydroindolo[3,2-d][1]benzazepinone kenpaullone, indirubin-3 -monoxime and novel diaminothiazoles such as AG12275. The anticancer therapeutic potential of CDK inhibitors has been demonstrated in preclinical studies, and Phases I and II clinical trials in cancer patients are currently underway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The potential of alkaloids in drug discovery
Cordell, G. A., Quinn‐Beattie, M. L., & Farnsworth, N. R. (2001) · Phytotherapy Research · doi:10.1002/ptr.890 · Cited by 374
Cell-cycle dysregulation and anticancer therapy
Stewart, Z. A., Westfall, M. D., & Pietenpol, J. A. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00026-9 · Cited by 344
Chemical Inhibitors of Protein Kinases
Bridges, A. J. (2001) · Chemical Reviews · doi:10.1021/cr000250y · Cited by 320
Anticancer and antiproliferative activity of natural brassinosteroids
Malíková, J., Swaczynová, J., Kolář, Z., & Strnad, M. (2008) · Phytochemistry · doi:10.1016/j.phytochem.2007.07.028 · Cited by 170
Hwang, S.-K., Jin, H., Kwon, J. T., Chang, S.-H., Kim, T. H., Cho, C.-S., Lee, K. H., Young, M. R., Colburn, N. H., Beck, G. R., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302983 · Cited by 44
Metadata
- Authors
- Buolamwini, J.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2000-03-01
- Volume
- 6
- Issue
- 4
- Pages
- 379-392
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W1999866626
- Cited by
- 238
- References
- 0
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cell Cycle Molecular Targets in Novel Anticancer Drug Discovery. https://app.cochat.ai/papers/10.2174/1381612003400948
- The paper
- Buolamwini, J. (2000). Cell Cycle Molecular Targets in Novel Anticancer Drug Discovery. Current Pharmaceutical Design. https://doi.org/10.2174/1381612003400948
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.